Sequana Medical NV: Sequana Medical to present at 8th Annual HealthTech Investment Forum

Participating in Next Generation Medtech & Device Panel on October 5^th, 2021

Ghent, Belgium - 28 September 2021- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will participate in a panel discussion at the 8^th Annual HealthTech Investment Forum (Sachs Forum), being held virtually on the 5^th and 6^th of October 2021.

The panel is entitled "The Next Generation Medtech and Device Panel" and is taking place on Tuesday, 5 October 2021 at 12:30 pm CET. To register for the event, click here.

To request a one-on-one meeting with the management of Sequana Medical, please check the online meeting platform of the event or contact us at [e-mail]. A Company presentation will be available on demand.

For more information, please contact:

Sequana Medical
Lies Vanneste, Director Investor Relations
Tel: [phone]
Email: [e-mail]

LifeSci Advisors
Guillaume van Renterghem
Tel: [phone]
Email: [e-mail]

About Sequana Medical

Sequana Medical is a commercial stage medical device company utilizing its proprietary alfapump and DSR (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a frequent complication of many large diseases including advanced liver disease driven by NASH (non-alcoholic steatohepatitis)-related cirrhosis and heart failure, with diuretic resistance being widespread. The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years. The heart failure market for DSR and the alfapump DSR is estimated to be over €5 billion annually in the U.S. and EU5 by 2026.

The alfapump is a unique, fully implanted wireless device that automatically pumps fluid from the abdominal cavity into the bladder, where it is naturally eliminated through urination. DSR is Sequana Medical's proprietary approach to managing sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity.

In the U.S., the Company's key growth market, the alfapump has been granted breakthrough device designation by the FDA for recurrent or refractory ascites due to liver cirrhosis. Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life. This study is intended to support a future marketing application of the alfapump in the U.S. and Canada. In Europe, the alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 850 alfapump systems have been implanted to date.

Sequana Medical has combined its proven alfapump and proprietary DSR therapy, and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure. RED DESERT, the repeated dose alfapump DSR study in diuretic-resistant heart failure patients has demonstrated that repeated DSR therapy is able to both manage the fluid and sodium balance of these patients as well as restore their diuretic response and improve their cardio-renal status. The SAHARA DESERT study of alfapump DSR in decompensated heart failure patients is ongoing.

Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

Important Regulatory Disclaimers

The alfapump system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump system is currently under clinical investigation. The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the alfapump system in Europe, the United States or Canada.

Note:alfapump is a registered trademark. DSR and alfapump DSR are registered trademarks in the Benelux.

Forward-looking statements

This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Attachments

• Press Release_HealthTech Investment Forum_DUTCH_28 Sept 2021_vF (https://ml-eu.globenewswire.com/Resource/Download/ad75b1f9-9bb3-4904-a1e9-91f32c5fe79d)
• Press Release_HealthTech Investment Forum_ENG_28 Sept 2021_vF (https://ml-eu.globenewswire.com/Resource/Download/68460682-4ac6-4d4e-a63c-1b6434224758)